| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3 is a synthetic intermediate used in the synthesis of Exatecan derivatives. As a peptide-based linker or building block, it does not have a direct pharmacological target itself. Its role is to serve as a precursor in the construction of more complex molecules, such as Exatecan derivatives, which are topoisomerase I inhibitors used in cancer research. The Fmoc group serves as a protecting group during peptide synthesis.
|
|---|---|
| ln Vitro |
In vitro activity of Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3 is not applicable in the traditional sense, as the compound is a synthetic intermediate rather than a pharmacologically active agent. Its biological activity, if any, would be derived from the final Exatecan derivatives synthesized using this intermediate. Exatecan derivatives are known to inhibit topoisomerase I, an enzyme involved in DNA replication and transcription.
|
| ln Vivo |
In vivo activity of Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3 is not applicable, as the compound is a synthetic intermediate rather than a pharmacologically active agent. Any in vivo activity would be associated with the final Exatecan derivatives synthesized from this intermediate. Exatecan derivatives are used in cancer research as topoisomerase I inhibitors.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3 is not applicable, as the compound is a synthetic intermediate used in peptide synthesis. It is not designed to interact with biological targets. Assays would be performed on the final Exatecan derivatives to evaluate their activity against topoisomerase I or other targets.
|
| Cell Assay |
In vitro cell-based assays for Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3 are not applicable, as the compound is a synthetic intermediate rather than a pharmacologically active agent. Cell-based assays would be performed on the final Exatecan derivatives synthesized using this intermediate to evaluate their anticancer activity against cancer cell lines.
|
| Animal Protocol |
In vivo animal studies for Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3 are not applicable, as the compound is a synthetic intermediate rather than a pharmacologically active agent. Animal studies would be conducted on the final Exatecan derivatives to evaluate their efficacy and toxicity in cancer models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3 include a molecular weight of 629.66 and a molecular formula of C33H35N5O8. As a synthetic intermediate, detailed pharmacokinetic data are not applicable. The compound is used in research for the synthesis of Exatecan derivatives. Storage and handling should follow standard procedures for peptide synthesis reagents.
|
| Toxicity/Toxicokinetics |
Toxicity information for Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3 is limited. Standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only. As a synthetic intermediate, its toxicity profile would be determined by the final drug product. No specific toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3 (compound DC-13-C) is a synthetic peptide derivative featuring an N-terminal Fmoc protecting group and a C-terminal acyl modification. It is an intermediate in the synthesis of Exatecan derivatives. Exatecan is a topoisomerase I inhibitor used in cancer research. The compound has a molecular formula of C33H35N5O8 and a molecular weight of 629.66.
|
| Exact Mass |
629.249
|
|---|---|
| CAS # |
2866301-96-2
|
| PubChem CID |
166138622
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
46
|
| Complexity |
1060
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=O)OCNC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24
|
| InChi Key |
XWQQDGZCBPDSMX-NDEPHWFRSA-N
|
| InChi Code |
InChI=1S/C33H35N5O8/c1-21(39)46-20-37-30(41)16-35-32(43)28(15-22-9-3-2-4-10-22)38-31(42)18-34-29(40)17-36-33(44)45-19-27-25-13-7-5-11-23(25)24-12-6-8-14-26(24)27/h2-14,27-28H,15-20H2,1H3,(H,34,40)(H,35,43)(H,36,44)(H,37,41)(H,38,42)/t28-/m0/s1
|
| Chemical Name |
[[2-[[(2S)-2-[[2-[[2-(9H-fluoren-9-ylmethoxycarbonylamino)acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]methyl acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~158.82 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one),clear solution.
For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 400 μL PEG300 and mix well. Then add 50 μL Tween-80 to the above system and mix well. Then continue to add 450 μL of physiological saline to make up to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.97 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one),clear solution. For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 900 μL of 20% SBE-β-CD saline solution and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one),clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
